Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience Corp LEXX has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the National Research Council (NRC).
The NRC has confirmed Lexaria's study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity.
Each drug tested remained stable and did not undergo a change in chemical structure.
The five drugs studied were remdesivir, ebastine, bepridil, rupintrivir, and colchicine.
These findings support accelerated regulatory filings authorizations of prospective DehydraTECH-enabled, repurposed antiviral drugs.
The Company will pursue collaboration opportunities with pharmaceutical partners to incorporate DehydraTECH technology with antiviral drugs, including or similar to those currently being investigated.
Price Action: LEXX shares are up 9.5% at $7.3 during the premarket session on the last check Thursday.